Over the past 12 months, Enanta Pharmaceuticals insiders sold $183,167 of stock on the open market (12.88K shares) and made no open-market purchases.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jay R. Luly | President And Ceo | 871,871 | 0 | 871,871 | 54.9% | 13 Feb, 2026 |
| 2 | Yat Sun Or | Chief Scientific Officer | 374,854 | 0 | 374,854 | 23.6% | 13 Feb, 2026 |
| 3 | Paul J Mellett | Chief Fin. Admin Officer | 95,884 | 0 | 95,884 | 6.0% | 14 Feb, 2025 |
| 4 | Nathaniel S. Gardiner | Chief Legal Officer | 75,688 | 0 | 75,688 | 4.8% | 27 Feb, 2024 |
| 5 | Brendan Luu | Chief Business Officer | 41,634 | 0 | 41,634 | 2.6% | 13 Feb, 2026 |
| 6 | Nathalie Adda | Sr. Vp Chief Medical Officer | 34,982 | 0 | 34,982 | 2.2% | 05 Apr, 2022 |
| 7 | Tara Lynn Kieffer | Chief Product Strategy Officer | 33,925 | 0 | 33,925 | 2.1% | 13 Feb, 2026 |
| 8 | Scott T. Rottinghaus | Chief Medical Officer | 23,787 | 0 | 23,787 | 1.5% | 10 Aug, 2026 |
| 9 | Harry R. Iii Trout | Officer | 16,348 | 0 | 16,348 | 1.0% | 05 Dec, 2025 |
| 10 | Kathleen S. Capps | Officer | 8,377 | 0 | 8,377 | 0.5% | 05 Dec, 2025 |
| 11 | Terry Vance | Director | 5,800 | 0 | 5,800 | 0.4% | 15 Dec, 2023 |
| 12 | Matthew Paul Kowalsky | Chief Legal Officer | 3,591 | 0 | 3,591 | 0.2% | 13 Feb, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 08 Aug, 2026 | Scott T. Rottinghaus | Chief Medical Officer | Disposed F | 1,467 | $13.34 | $19.57K | 23,787 | Direct |
| 11 Mar, 2026 | Mark G Foletta | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Terry Vance | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Yujiro S Hata | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Lesley Russell | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Bruce L A Carter | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Kristine Peterson | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 12 Feb, 2026 | Brendan Luu | Chief Business Officer | Acquired A | 1,575 | $0.00 | $0 | 39,904 | Direct |
| 12 Feb, 2026 | Jay R. Luly | President And Ceo | Acquired A | 4,800 | $0.00 | $0 | 862,826 | Direct |
| 12 Feb, 2026 | Scott T. Rottinghaus | Chief Medical Officer | Acquired A | 1,650 | $0.00 | $0 | 23,442 | Direct |
| 12 Feb, 2026 | Yat Sun Or | Chief Scientific Officer | Acquired A | 1,650 | $0.00 | $0 | 373,042 | Direct |
| 12 Feb, 2026 | Matthew Paul Kowalsky | Chief Legal Officer | Acquired A | 1,318 | $0.00 | $0 | 1,318 | Direct |
| 12 Feb, 2026 | Tara Lynn Kieffer | Chief Product Strategy Officer | Acquired A | 1,575 | $0.00 | $0 | 32,195 | Direct |
| 12 Feb, 2026 | Yat Sun Or | Chief Scientific Officer | Acquired A | 5,225 | $0.00 | $0 | 378,267 | Direct |
| 12 Feb, 2026 | Matthew Paul Kowalsky | Chief Legal Officer | Acquired A | 4,175 | $0.00 | $0 | 5,493 | Direct |
| 12 Feb, 2026 | Scott T. Rottinghaus | Chief Medical Officer | Acquired A | 5,225 | $0.00 | $0 | 28,667 | Direct |
| 12 Feb, 2026 | Jay R. Luly | President And Ceo | Acquired A | 15,200 | $0.00 | $0 | 878,026 | Direct |
| 12 Feb, 2026 | Brendan Luu | Chief Business Officer | Acquired A | 4,987 | $0.00 | $0 | 44,891 | Direct |
| 12 Feb, 2026 | Tara Lynn Kieffer | Chief Product Strategy Officer | Acquired A | 4,987 | $0.00 | $0 | 37,182 | Direct |
| 12 Feb, 2026 | Jay R. Luly | President And Ceo | Disposed F | 6,155 | $14.25 | $87.71K | 871,871 | Direct |